Sarepta Therapeutics, Inc.
SRPT
$18.10
-$0.32-1.74%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -101.48% | 217.01% | -57.18% | -191.39% | 144.00% |
| Total Depreciation and Amortization | -1.75% | 101.68% | -71.53% | 70.20% | 8.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 14.74% | -39.36% | -60.66% | 4,226.70% | -97.00% |
| Change in Net Operating Assets | 124.45% | -272.68% | 1,261.59% | -159.01% | 117.58% |
| Cash from Operations | 197.23% | -254.48% | 999.60% | -105.58% | 144.79% |
| Capital Expenditure | 73.33% | 42.05% | 84.34% | 27.87% | 27.16% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 29.85% | -232.58% | -60.91% | 298.92% | 125.86% |
| Cash from Investing | 30.52% | -239.69% | -58.60% | 621.49% | 111.06% |
| Total Debt Issued | -30.00% | -- | -- | -- | -- |
| Total Debt Repaid | 30.00% | -611.58% | 71.65% | -40,670.07% | 90.53% |
| Issuance of Common Stock | -100.00% | -21.75% | -98.55% | 1,314.27% | -90.43% |
| Repurchase of Common Stock | -- | -- | -- | 100.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 70.90% | -- | -- |
| Cash from Financing | -100.00% | 100.61% | 66.71% | -394.56% | -290.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 130.79% | -278.97% | 88.16% | -62.92% | 131.29% |